393 related articles for article (PubMed ID: 29726361)
1. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation.
Ho AY; Olm-Shipman M; Zhang Z; Siu CT; Wilgucki M; Phung A; Arnold BB; Porinchak M; Lacouture M; McCormick B; Powell SN; Gelblum DY
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):325-333. PubMed ID: 29726361
[TBL] [Abstract][Full Text] [Related]
2. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4.
Miller RC; Schwartz DJ; Sloan JA; Griffin PC; Deming RL; Anders JC; Stoffel TJ; Haselow RE; Schaefer PL; Bearden JD; Atherton PJ; Loprinzi CL; Martenson JA
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1460-6. PubMed ID: 20800381
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of severe skin toxicity and pain during postmastectomy radiation therapy.
Pignol JP; Vu TT; Mitera G; Bosnic S; Verkooijen HM; Truong P
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):157-64. PubMed ID: 25835623
[TBL] [Abstract][Full Text] [Related]
4. Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial.
Hindley A; Zain Z; Wood L; Whitehead A; Sanneh A; Barber D; Hornsby R
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):748-55. PubMed ID: 25585779
[TBL] [Abstract][Full Text] [Related]
5. A prospective feasibility study of a 1-mm bolus for postmastectomy radiotherapy.
Kawamoto T; Shikama N; Kurokawa C; Hara N; Oshima M; Sasai K
BMC Cancer; 2021 Feb; 21(1):109. PubMed ID: 33530984
[TBL] [Abstract][Full Text] [Related]
6. A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients.
Ingargiola R; De Santis MC; Iacovelli NA; Facchinetti N; Cavallo A; Ivaldi E; Dispinzieri M; Franceschini M; Giandini C; Romanello DA; Di Biaso S; Sabetti M; Locati L; Alfieri S; Bossi P; Guglielmo M; Macchi F; Lozza L; Valdagni R; Fallai C; Pignoli E; Orlandi E
Radiat Oncol; 2020 Aug; 15(1):193. PubMed ID: 32791985
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic NS-21 maintains the skin moisture but does not reduce the severity of radiation dermatitis in patients with head and neck cancer: a randomized control trial.
Chou HL; Shueng PW; Liao LJ; Hsu CX; Kuo DY; Lo WC; Hou PY; Wang LY; Chou SF; Hsieh CH
Radiat Oncol; 2019 May; 14(1):90. PubMed ID: 31146741
[TBL] [Abstract][Full Text] [Related]
8. Double-Blind, Placebo-Controlled Pilot Study of Processed Ultra Emu Oil Versus Placebo in the Prevention of Radiation Dermatitis.
Rollmann DC; Novotny PJ; Petersen IA; Garces YI; Bauer HJ; Yan ES; Wahner-Roedler D; Vincent A; Sloan JA; Issa Laack NN
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):650-8. PubMed ID: 25936812
[TBL] [Abstract][Full Text] [Related]
9. Randomized, self-controlled, prospective assessment of the efficacy of mometasone furoate local application in reducing acute radiation dermatitis in patients with head and neck squamous cell carcinomas.
Liao Y; Feng G; Dai T; Long F; Tang J; Pu Y; Zheng X; Cao S; Xu S; Du X
Medicine (Baltimore); 2019 Dec; 98(52):e18230. PubMed ID: 31876704
[TBL] [Abstract][Full Text] [Related]
10. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study.
Boström A; Lindman H; Swartling C; Berne B; Bergh J
Radiother Oncol; 2001 Jun; 59(3):257-65. PubMed ID: 11369066
[TBL] [Abstract][Full Text] [Related]
11. Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4).
Neben-Wittich MA; Atherton PJ; Schwartz DJ; Sloan JA; Griffin PC; Deming RL; Anders JC; Loprinzi CL; Burger KN; Martenson JA; Miller RC
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):397-402. PubMed ID: 20888137
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Prospective, Open-label Phase III Trial Comparing Mebo Ointment With Biafine Cream for the Management of Acute Dermatitis During Radiotherapy for Breast Cancer.
Geara FB; Eid T; Zouain N; Thebian R; Andraos T; Chehab C; Ramia P; Youssef B; Zeidan YH
Am J Clin Oncol; 2018 Dec; 41(12):1257-1262. PubMed ID: 29889137
[TBL] [Abstract][Full Text] [Related]
13. Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]).
Sio TT; Atherton PJ; Birckhead BJ; Schwartz DJ; Sloan JA; Seisler DK; Martenson JA; Loprinzi CL; Griffin PC; Morton RF; Anders JC; Stoffel TJ; Haselow RE; Mowat RB; Wittich MA; Bearden JD; Miller RC
Support Care Cancer; 2016 Sep; 24(9):3847-55. PubMed ID: 27075674
[TBL] [Abstract][Full Text] [Related]
14. Racial variations in radiation-induced skin toxicity severity: data from a prospective cohort receiving postmastectomy radiation.
Wright JL; Takita C; Reis IM; Zhao W; Lee E; Hu JJ
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):335-43. PubMed ID: 25304794
[TBL] [Abstract][Full Text] [Related]
15. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis.
Pignol JP; Olivotto I; Rakovitch E; Gardner S; Sixel K; Beckham W; Vu TT; Truong P; Ackerman I; Paszat L
J Clin Oncol; 2008 May; 26(13):2085-92. PubMed ID: 18285602
[TBL] [Abstract][Full Text] [Related]
16. Nigella sativa L. for prevention of acute radiation dermatitis in breast cancer: A randomized, double-blind, placebo-controlled, clinical trial.
Rafati M; Ghasemi A; Saeedi M; Habibi E; Salehifar E; Mosazadeh M; Maham M
Complement Ther Med; 2019 Dec; 47():102205. PubMed ID: 31780017
[TBL] [Abstract][Full Text] [Related]
17. Phase II study assessing the effectiveness of Biafine cream as a prophylactic agent for radiation-induced acute skin toxicity to the breast in women undergoing radiotherapy with concomitant CMF chemotherapy.
Szumacher E; Wighton A; Franssen E; Chow E; Tsao M; Ackerman I; Andersson L; Kim J; Wojcicka A; Ung Y; Sixel K; Hayter C
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):81-6. PubMed ID: 11516855
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind trial on the use of 1% hydrocortisone cream for the prevention of acute radiation dermatitis.
Meghrajani CF; Co HS; Arcillas JG; Maaño CC; Cupino NA
Expert Rev Clin Pharmacol; 2016; 9(3):483-91. PubMed ID: 26619355
[TBL] [Abstract][Full Text] [Related]
19. Biophysical skin measurements to evaluate the effectiveness of photobiomodulation therapy in the prevention of acute radiation dermatitis in breast cancer patients.
Robijns J; Censabella S; Claes S; Pannekoeke L; Bussé L; Colson D; Kaminski I; Lodewijckx J; Bulens P; Maes A; Noé L; Brosens M; Timmermans A; Lambrichts I; Somers V; Mebis J
Support Care Cancer; 2019 Apr; 27(4):1245-1254. PubMed ID: 30270415
[TBL] [Abstract][Full Text] [Related]
20. 3M Cavilon No-Sting Barrier Film or topical corticosteroid (mometasone furoate) for protection against radiation dermatitis: A clinical trial.
Shaw SZ; Nien HH; Wu CJ; Lui LT; Su JF; Lang CH
J Formos Med Assoc; 2015 May; 114(5):407-14. PubMed ID: 23685085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
